GoAI
Get started
Fate Therapeutics, Inc. logo

Fate Therapeutics, Inc.

FATE

NASDAQHealthcareBiotechnology

Open in GoAI

Previous close

$2.33

−$0.12 · -4.90%

Aug 21, 4:00 PM ET

Pre-market

$2.33

$0.00 · 0.00%

Aug 24, 8:37 AM ET

FATE company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Hold

Wait — insufficient conviction to act

Valuation

9

Overpriced

Momentum

90

Strong Up

Sentiment

72

Bullish

Risk resilience

44

Elevated Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

Fate Therapeutics, Inc. is a clinical-stage biopharmaceutical firm dedicated to creating advanced, programmed cellular immunotherapies. These innovative treatments are designed to combat cancer and various immune disorders across the globe. A significant portion of its development pipeline concentrates on NK- and T-cell immuno-oncology programs. Key candidates include FT516, which targets acute myeloid leukemia (AML), B-cell lymphoma, and advanced solid tumors; FT596 for B-cell lymphoma and chronic lymphocytic leukemia; FT538, addressing AML and multiple myeloma; FT576, also focused on multiple myeloma; FT819, aimed at both hematologic malignancies and solid tumors; FT536, another program for solid tumors; and FT500, intended for advanced solid tumors. The company also actively engages in strategic collaborations to advance its research and development. It holds an agreement with Ono Pharmaceutical Co. Ltd. for the joint development and commercialization of two novel, "off-the-shelf" iPSC-derived CAR T-cell therapies. Furthermore, Fate Therapeutics maintains a research collaboration and licensing deal with Juno Therapeutics, Inc., focusing on identifying small molecule modulators that can enhance the therapeutic efficacy of genetically engineered T-cell immunotherapies. A separate collaboration and option agreement exists with Janssen Biotech, Inc. Established in 2007, Fate Therapeutics, Inc. is based in San Diego, California.

Industry
Biotechnology
Sector
Healthcare
Headquarters
US
CEO
Bahram Valamehr
Listed since
Oct 1, 2013
Employees
161

Market position

Day range

Current $2.33

52-week range

Current $2.33

Open
$2.49
Previous close
$2.45
Volume
1.7M
0.5× average
Average volume
3.43M
Average daily volume
Market cap
271.58M USD
Beta
2.55
Market reference 1
50-day average
$2.5428
-8.37% below average
200-day average
$1.6543
+40.85% above average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
147.94M USD
P/E (TTM)
-2.22×
P/B (TTM)
1.83×
P/S (TTM)
41.84×
EV / EBITDA
-1.16×
Earnings yield
-116.79%
Free cash flow yield
-95.99%
Dividend yield
0.00%

Profitability & efficiency

Gross margin
-343.01%
Operating margin
-2058.08%
Net margin
-1941.09%
Return on equity
-65.79%
Return on assets
-42.74%
Return on invested capital
-51.39%

Financial health

Debt / equity
0.49×
Current ratio
5.79×
Altman Z-score
-8.06
Piotroski F-score
3 of 9

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends321%-604%-1529%-2454%Gross margin, FY2021: 89.52%Gross margin, FY2022: 85.71%Gross margin, FY2023: -147.41%Gross margin, FY2024: -769.57%Gross margin, FY2025: -94.12%Operating margin, FY2021: -388.56%Operating margin, FY2022: -320.23%Operating margin, FY2023: -299.86%Operating margin, FY2024: -1542.63%Operating margin, FY2025: -2222.45%Net margin, FY2021: -379.89%Net margin, FY2022: -292.55%Net margin, FY2023: -253.30%Net margin, FY2024: -1366.46%Net margin, FY2025: -2051.08%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2021 89.52%. Gross margin FY2022 85.71%. Gross margin FY2023 -147.41%. Gross margin FY2024 -769.57%. Gross margin FY2025 -94.12%. Operating margin FY2021 -388.56%. Operating margin FY2022 -320.23%. Operating margin FY2023 -299.86%. Operating margin FY2024 -1542.63%. Operating margin FY2025 -2222.45%. Net margin FY2021 -379.89%. Net margin FY2022 -292.55%. Net margin FY2023 -253.30%. Net margin FY2024 -1366.46%. Net margin FY2025 -2051.08%.

Income trends

Revenue

6.65M USD-51.24%

Operating income

−147.7M USD+29.76%

Net income

−136.32M USD+26.82%
Income trends across reported periods136.77M USD−25.11M USD−186.98M USD−348.85M USDRevenue, FY2021: 55.85M USDRevenue, FY2022: 96.3M USDRevenue, FY2023: 63.53M USDRevenue, FY2024: 13.63M USDRevenue, FY2025: 6.65M USDOperating income, FY2021: −216.99M USDOperating income, FY2022: −308.39M USDOperating income, FY2023: −190.51M USDOperating income, FY2024: −210.28M USDOperating income, FY2025: −147.7M USDNet income, FY2021: −212.15M USDNet income, FY2022: −281.72M USDNet income, FY2023: −160.93M USDNet income, FY2024: −186.26M USDNet income, FY2025: −136.32M USDFY2021FY2022FY2023FY2024FY2025
Revenue FY2021 55.85M USD. Revenue FY2022 96.3M USD. Revenue FY2023 63.53M USD. Revenue FY2024 13.63M USD. Revenue FY2025 6.65M USD. Operating income FY2021 −216.99M USD. Operating income FY2022 −308.39M USD. Operating income FY2023 −190.51M USD. Operating income FY2024 −210.28M USD. Operating income FY2025 −147.7M USD. Net income FY2021 −212.15M USD. Net income FY2022 −281.72M USD. Net income FY2023 −160.93M USD. Net income FY2024 −186.26M USD. Net income FY2025 −136.32M USD.
Metric (USD)FY2025FY2024FY2023FY2022FY2021
Revenue6.65M USD13.63M USD63.53M USD96.3M USD55.85M USD
Cost of goods sold12.9M USD118.53M USD157.19M USD13.76M USD5.85M USD
Gross profit−6.26M USD−104.9M USD−93.65M USD82.54M USD50M USD
Research and development107.83M USD135M USD172.6M USD320.45M USD215.52M USD
Selling, general, and administrative46.52M USD90.64M USD96.86M USD84.23M USD57.32M USD
Operating expenses141.45M USD105.38M USD96.86M USD390.93M USD266.99M USD
Interest income11.05M USD17.29M USD17.19M USD5.84M USD1.31M USD
Depreciation and amortization9.3M USD18.96M USD18.28M USD13.76M USD5.85M USD
Operating income−147.7M USD−210.28M USD−190.51M USD−308.39M USD−216.99M USD
Net income−136.32M USD−186.26M USD−160.93M USD−281.72M USD−212.15M USD

Company facts updated Aug 24, 2026.

Earnings

EPS beat rate
73%
8 beats, 0 misses, 3 met estimates
Average EPS surprise
+9.94%
11 comparable reports
Latest EPS result
-0.25
Estimate -0.25 · Beat by 1.44%

EPS: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly EPS actual values compared with estimates-0.21-0.3-0.39-0.48Q1 '25MetQ2 '25BeatQ3 '25BeatQ4 '25BeatQ1 '26MetQ2 '26BeatQ3 '26BeatQ4 '26Estimate
Q1 2025, reported Mar 5, 2025: actual -0.44, estimate -0.44, surprise 0.00%, Met estimate. Q2 2025, reported May 13, 2025: actual -0.32, estimate -0.39, surprise +17.95%, Beat. Q3 2025, reported Aug 12, 2025: actual -0.29, estimate -0.35, surprise +17.14%, Beat. Q4 2025, reported Nov 13, 2025: actual -0.27, estimate -0.29, surprise +6.90%, Beat. Q1 2026, reported Feb 26, 2026: actual -0.27, estimate -0.27, surprise 0.00%, Met estimate. Q2 2026, reported May 13, 2026: actual -0.26, estimate -0.29, surprise +10.34%, Beat. Q3 2026, reported Aug 13, 2026: actual -0.25, estimate -0.254, surprise +1.44%, Beat. Q4 2026, reported Nov 12, 2026: actual —, estimate -0.27, surprise —, Comparison unavailable.

Revenue: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly Revenue actual values compared with estimates2.17M1.8M1.43M1.07MQ1 '25BeatQ2 '25BeatQ3 '25BeatQ4 '25BeatQ1 '26BeatQ2 '26MissQ3 '26BeatQ4 '26Estimate
Q1 2025, reported Mar 5, 2025: actual 1.86M USD, estimate 1.37M USD, surprise +35.44%, Beat. Q2 2025, reported May 13, 2025: actual 1.63M USD, estimate 1.18M USD, surprise +37.53%, Beat. Q3 2025, reported Aug 12, 2025: actual 1.91M USD, estimate 1.15M USD, surprise +65.98%, Beat. Q4 2025, reported Nov 13, 2025: actual 1.74M USD, estimate 1.2M USD, surprise +45.31%, Beat. Q1 2026, reported Feb 26, 2026: actual 1.37M USD, estimate 1.34M USD, surprise +2.42%, Beat. Q2 2026, reported May 13, 2026: actual 1.3M USD, estimate 1.49M USD, surprise -12.93%, Miss. Q3 2026, reported Aug 13, 2026: actual 2.08M USD, estimate 1.94M USD, surprise +7.10%, Beat. Q4 2026, reported Nov 12, 2026: actual —, estimate 1.2M USD, surprise —, Comparison unavailable.

Analyst ratings

Third-party consensus; not a GoAI recommendation.

Analyst price target

Average target

$5.63

141.63% upside
Past 12 months12-month forecastHigh $8.00Average $5.63Low $3.50

Rating distribution

31 ratings
Strong buy00%
Buy1652%
Hold1342%
Sell26%
Strong sell00%

Recent analyst actions

12 institutions
BairdmaintainNeutral
StifelmaintainHold

FATE news

globenewswire.com

Fate Therapeutics Initiates Potentially Registrational RECLAIM-LN Clinical Trial of FT819 for the Treatment of Lupus Nephritis

First patient dosed in an outpatient setting, discharged the same day; multiple patients in the process of screening at several activated sites

Read source
zacks.com

Fate Therapeutics (FATE) Reports Q2 Loss, Tops Revenue Estimates

Fate Therapeutics (FATE) came out with a quarterly loss of $0.25 per share versus the Zacks Consensus Estimate of a loss of $0.28. This compares to a loss of $0.29 per share a year ago.

Read source
globenewswire.com

Fate Therapeutics Reports Second Quarter 2026 Financial Results and Business Updates

First lupus nephritis patient dosed in RECLAIM-LN, a Phase 2 potentially registrational trial utilizing FT819, an iPSC-derived, off-the-shelf CAR T-cell therapy; patient was treated as an outpatient with same-day…

Read source
youtube.com

FATE UNKNOWN: If CLARITY DIES Democrats KILLED IT, Lummis says

Sen. Cynthia Lummis, R-Wyo., discusses the expected CLARITY Act vote, the budget agenda before recess, Congress' August checklist and the Democratic Party's direction after Tuesday's primaries on ‘Mornings with Maria.

Read source
globenewswire.com

Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

SAN DIEGO, Aug. 03, 2026 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a transformative pipeline of induced pluripotent stem cell…

Read source
globenewswire.com

Fate Therapeutics Receives FDA Clearance of Investigational New Drug Application for FT839 Product Candidate

First-of-Kind, Dual-CAR T cell Targeting CD19 and CD38 for Comprehensive Elimination of Complex, Multi-System Autoimmune Disorders Advances into Phase 1/2 Clinical Development

Read source

FATE peers

Amgen Inc. logo

AMGN

Amgen Inc.

$439.33

+1.29%

Gilead Sciences, Inc. logo

GILD

Gilead Sciences, Inc.

$146.12

+1.87%

Vertex Pharmaceuticals Incorporated logo

VRTX

Vertex Pharmaceuticals Incorporated

$548.05

+1.44%

Intuitive Surgical, Inc. logo

ISRG

Intuitive Surgical, Inc.

$378.81

+1.16%

Sanofi logo

SNY

Sanofi

$45.85

+1.55%

Regeneron Pharmaceuticals, Inc. logo

REGN

Regeneron Pharmaceuticals, Inc.

$834.04

+0.90%

ETFs holding FATE

Funds reporting this stock among their holdings, ordered by reported position size.

Vanguard Morningstar Total Stock Market ETF logoVanguard Morningstar Total Stock Market ETFVTI
Market value
7.83M
Weight
0.00%
AUM
2.3T USD
Expense ratio
0.03%
Price / 1D
$378.24+0.44%
Vanguard Extended Market ETF logoVanguard Extended Market ETFVXF
Market value
2.92M
Weight
0.00%
AUM
93.7B USD
Expense ratio
0.05%
Price / 1D
$245.53+0.82%
Schwab U.S. Small-Cap ETF logoSchwab U.S. Small-Cap ETFSCHA
Market value
1.17M
Weight
0.01%
AUM
23.1B USD
Expense ratio
0.03%
Price / 1D
$34.83+0.52%
iShares Micro-Cap ETF logoiShares Micro-Cap ETFIWC
Market value
967.97K
Weight
0.06%
AUM
1.53B USD
Expense ratio
0.60%
Price / 1D
$198.39+1.10%
Vanguard Health Care ETF logoVanguard Health Care ETFVHT
Market value
693.43K
Weight
0.00%
AUM
20.9B USD
Expense ratio
0.09%
Price / 1D
$327.7+1.24%
Invesco RAFI US 1500 Small-Mid ETF logoInvesco RAFI US 1500 Small-Mid ETFPRFZ
Market value
557.41K
Weight
0.02%
AUM
2.87B USD
Expense ratio
0.34%
Price / 1D
$55.89+0.87%
Avantis U.S. Small Cap Equity ETF logoAvantis U.S. Small Cap Equity ETFAVSC
Market value
270.27K
Weight
0.01%
AUM
3.16B USD
Expense ratio
0.25%
Price / 1D
$73.84+0.70%
Schwab U.S. Broad Market ETF logoSchwab U.S. Broad Market ETFSCHB
Market value
257.47K
Weight
0.00%
AUM
44.6B USD
Expense ratio
0.03%
Price / 1D
$29.61+0.48%

Continue in GoAI

Research FATE

research.disclaimer